Not Yet RecruitingPhase 2ACTRN12612000864820

Investigation of whether metformin can be used safely and effectively in patients with type 2 diabetes on peritoneal dialysis

A short term study of safety and glycaemic outcomes in peritoneal dialysis patients with type 2 diabetes treated with metformin

Sponsor

Tilenka Thynne

Enrollment

6 participants

Start Date

Sep 1, 2012

Study Type

Interventional

Conditions

Chronic kidney Disease- on peritoneal dialysis Type 2 Diabetes

Summary

This is a study aiming to evaluate whether metformin, an antidiabetic medication, can be used safety and effectively in patients with type 2 diabetes who are receiving peritoneal dialysis for their end stage kidney disease. The study runs over 4 weeks of active treatment, 250mg of metformin daily orally. We hypothesise that metformin can be safely used in patients with type 2 diabetes with end stage renal failure if dosed based on predicted drug clearance.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 100 Yearss

Inclusion Criteria4

(1)>18 years old
(2)Type 2 DM
(3)Peritoneal Dialysis treatment of chronic kidney disease
(4)Patients in whom metformin would be used if they had normal renal function

Exclusion Criteria3

(1)Any patient in whom metofrmin would not be used in the setting of normal renal function- moderate-severe heart failure, liver failure, alcohol abuse, major psychaitric disorder, acutely unwell or otherwise medically unstable.
(2)Unability or unwilling to measure own blood glucose concentrations via glucometer.
(3)Inability to provide written informed consent.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Metformin 250 mg orally (half a 500mg tablet once a day) for 4 weeks of active treatment while continuing participants' existing peritoneal dialysis treatment. Peritoneal dialysis is not standardised